These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8695822)

  • 1. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging.
    Bergan R; Hakim F; Schwartz GN; Kyle E; Cepada R; Szabo JM; Fowler D; Gress R; Neckers L
    Blood; 1996 Jul; 88(2):731-41. PubMed ID: 8695822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
    Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
    Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma.
    Williams SA; Gillan ER; Knoppel E; Buzby JS; Suen Y; Cairo MS
    Ann Oncol; 1997; 8 Suppl 1():25-30. PubMed ID: 9187425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow purging with antisense oligodeoxynucleotides.
    Gewirtz AM
    Prog Clin Biol Res; 1992; 377():215-24; discussion 225-6. PubMed ID: 1438418
    [No Abstract]   [Full Text] [Related]  

  • 6. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
    LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
    Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo bone marrow purging with oligonucleotides.
    Bergan RC
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):251-5. PubMed ID: 9212920
    [No Abstract]   [Full Text] [Related]  

  • 8. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
    Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
    Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
    J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction.
    Merino ME; Navid F; Christensen BL; Toretsky JA; Helman LJ; Cheung NK; Mackall CL
    J Clin Oncol; 2001 Aug; 19(16):3649-59. PubMed ID: 11504746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.
    Calabretta B; Sims RB; Valtieri M; Caracciolo D; Szczylik C; Venturelli D; Ratajczak M; Beran M; Gewirtz AM
    Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2351-5. PubMed ID: 2006173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging.
    Uckun FM; Kersey JH; Haake R; Weisdorf D; Ramsay NK
    Blood; 1992 Feb; 79(4):1094-104. PubMed ID: 1531306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
    de Fabritiis P; Amadori S; Calabretta B; Mandelli F
    Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
    Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
    Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
    Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
    Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
    Skala JP; Rogers PC; Chan KW; Rodriguez WC
    Prog Clin Biol Res; 1992; 377():57-62. PubMed ID: 1332075
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of purging clonogenic leukemia cells using ether lipid and hyperthermia for autologous bone marrow transplantation.
    Min WS; Park HM; Han CH; Park JW; Kim CC; Kim DJ
    Prog Clin Biol Res; 1992; 377():87-95. PubMed ID: 1438449
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
    Gidáli J; Fehér I
    Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow.
    Kramer B; Makrynikola V; Bradstock K
    Prog Clin Biol Res; 1992; 377():41-7. PubMed ID: 1438438
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.
    Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D
    Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.